^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
irinotecan liposomal
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CSPC Pharma
Drug class:
Topoisomerase I inhibitor
Related drugs:
6d
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. (PubMed, Nat Commun)
In this phase 2 study (NCT05047991), patients with unresectable metastatic pancreatic adenocarcinoma were randomized to receive NALIRIFOX (liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin) or gemcitabine plus nab-paclitaxel...≥ Grade 3 treatment-emergent adverse events (TEAEs) occurred in 73.1% of patients receiving NALIRIFOX and 84.6% of patients receiving gemcitabine plus nab-paclitaxel, respectively. Despite the premature termination (predetermined sample size of n = 153 not reached) of the study, NALIRIFOX demonstrated improvement in PFS compared with gemcitabine plus nab-paclitaxel, with a manageable safety profile in Chinese patients with advanced pancreatic adenocarcinoma.
P2 data • Journal
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
|
gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • irinotecan liposomal
3ms
Irinotecan hydrochloride liposome injection combined with oxaliplatin and 5-FU/LV for the treatment of liver metastasis from advanced pancreatic cancer: A multicenter, open-access, Phase II exploratory study (ChiCTR2500109550)
P2, N=30, Not yet recruiting, China-Japan Friendship Hospital; China-Japan Friendship Hospital
New P2 trial
|
5-fluorouracil • irinotecan liposomal
6ms
Phase I/II exploratory study of irinotecan liposome + capecitabine + oxaliplatin in the treatment of patients with borderline resectable/locally advanced pancreatic cancer (ChiCTR2500107156)
P1/2, N=48, Not yet recruiting, Peking University First Hospital; Peking University First Hospital
New P1/2 trial
|
capecitabine • irinotecan liposomal
6ms
A prospective, single-arm phase II clinical study of liposomal irinotecan in combination with interleukin-2 and sintilimab in the second-line treatment of patients with advanced gastric cancer (ChiCTR2500106811)
P1, N=45, Not yet recruiting, Gaoxin Hospital of The First Affiliated Hospital of Nanchang University; Gaoxin Hospital of The First Affiliated Hospital of Nanchang University
New P1 trial
|
Tyvyt (sintilimab) • irinotecan liposomal
6ms
Phase II Study of Irinotecan Liposomes Combined With 5-FU/LV+ Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer (ChiCTR2500104331)
P2, N=86, Completed, West China Hospital of Sichuan University; West China Hospital of Sichuan University
New P2 trial
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • RAS mutation
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan liposomal
8ms
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma (clinicaltrials.gov)
P4, N=45, Not yet recruiting, Beijing GoBroad Hospital
New P4 trial
|
5-fluorouracil • irinotecan liposomal
8ms
Irinotecan Liposomes with Capecitabine and Bevacizumab for the Elderly Colorectal Cancer Patients Failed to Oxaliplatin-based Regimen: The LIVE Study (ChiCTR2500100308)
P4, N=31, Not yet recruiting, The Affiliated Hospital of Fudan University, Hua Shan; The Affiliated Hospital of Fudan University, Hua Shan
New P4 trial
|
MSI (Microsatellite instability)
|
Avastin (bevacizumab) • capecitabine • oxaliplatin • irinotecan liposomal
10ms
Irinotecan liposome combined with capecitabine + sintilimab +/- bevacizumab as first-line therapy for patients with RAS mutation and MSS-type metastatic colorectal cancer (ChiCTR2500097870)
P2, N=30, Not yet recruiting, Sichuan Cancer Hospital; Sichuan Cancer Hospital
New P2 trial
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type • RAS mutation
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • capecitabine • irinotecan liposomal
1year
The efficacy and safety research of irinotecan liposome injection combined with 5-FU/LV for HAIC+- Sindillizumab and Bevacizumab in the treatment of unresectable advanced biliary tract cancer (ChiCTR2400092319)
P=N/A, N=30, Affiliation Hospital of JiangNan University; Affiliation Hospital of JiangNan University
New trial
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan liposomal
1year
Single-arm, multicenter, exploratory clinical study of irinotecan liposomes combined with oxaliplatin and 5-Fu/Lv in second-line treatment of locally advanced or metastatic pancreatic cancer (ChiCTR2400094119)
P4, N=38, Wuxi People's Hospital; Wuxi People's Hospital
New P4 trial
|
5-fluorouracil • oxaliplatin • irinotecan liposomal
1year
A Study on Irinotecan Liposome Injection for Neoadjuvant Treatment of Colorectal Cancer Patients (ChiCTR2400092630)
P2, N=30, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
New P2 trial
|
5-fluorouracil • oxaliplatin • irinotecan liposomal
1year
Phase I clinical study of irinotecan liposome combined with furoquininib in the third-line and beyond patients with advanced colorectal cancer (ChiCTR2400092084)
P1, N=18, Guangxi Medical University Cancer Hospital; Guangxi Medical University Cancer Hospital
New P1 trial
|
irinotecan liposomal
Share via
